Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis (Q28540630)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 2014)

Language	Label	Description	Also known as
English	Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis	scientific article (publication date: 2014)

Statements

scholarly article

0 references

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis (English)

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

object named as

Jenny Link

1

0 references

object named as

Ingrid Kockum

7

0 references

author name string

Malin Lundkvist Ryner

2

0 references

Katharina Fink

3

0 references

Christina Hermanrud

4

0 references

Izaura Lima

5

0 references

Boel Brynedal

6

0 references

Jan Hillert

8

0 references

Anna Fogdell-Hahn

9

0 references

language of work or name

0 references

publication date

2014

0 references

0 references

9

0 references

3

0 references

e90479

0 references

copyright license

Creative Commons Attribution 4.0 International

7 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

describes a project that uses

1 reference

Europe PubMed Central

18 June 2022

https://europepmc.org/article/PMC/3946519

based on heuristic

inferred from PubMed Central ID database lookup

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

19 March 2017

Multi-population classical HLA type imputation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Promise and pitfalls of the Immunochip

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Post-translational modifications of naturally processed MHC-binding epitopes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Glycan side chains on naturally presented MHC class II ligands.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Immunogenicity of interferon beta: differences among products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

29 September 2017

Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

3 June 2018

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

3 June 2018

HLA*IMP--an integrated framework for imputing classical HLA alleles from SNP genotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

3 June 2018

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

3 June 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0090479

21 January 2018

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3946519

27 November 2018

Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of neutralization of interferon by antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24608124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0090479

0 references

2014PLoSO...990479L

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28540630&oldid=1862382835"